Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mukherjee

Showing results (361-370 of 413) with videos related to

Pageof 42
Sort By:
Circulation|December 6, 2001
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromesM Roffi, D P Chew, D Mukherjee, et al.
European Heart Journal|September 5, 2002
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategyM Roffi, D P Chew, D Mukherjee, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancerEric K Nguyen, Hang Yu, Gregory Pond, et al.
Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Developmental Biology|October 11, 2014
Alk3 mediated Bmp signaling controls the contribution of epicardially derived cells to the tissues of the atrioventricular junctionMarie M Lockhart, Bastiaan J D Boukens, Aimee L Phelps, et al.
Biomedicines|January 21, 2023
Biofilms on Indwelling Artificial Urinary Sphincter Devices Harbor Complex Microbe-Metabolite Interaction Networks and Reconstitute Differentially In Vitro by Material TypeGlenn T Werneburg, Daniel Hettel, Ava Adler, et al.
JACC. Cardiooncology|August 16, 2021
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I TrialDarryl P Leong, Tammy Cosman, Muhammad M Alhussein, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 7, 2019
Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinomaMark Warren, Michael Kolinsky, Christina M Canil, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Pageof 42

Showing results (361-370 of 413) with videos related to

Sort By:
Pageof 42
Circulation|December 6, 2001
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromesM Roffi, D P Chew, D Mukherjee, et al.
European Heart Journal|September 5, 2002
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategyM Roffi, D P Chew, D Mukherjee, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancerEric K Nguyen, Hang Yu, Gregory Pond, et al.
Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Developmental Biology|October 11, 2014
Alk3 mediated Bmp signaling controls the contribution of epicardially derived cells to the tissues of the atrioventricular junctionMarie M Lockhart, Bastiaan J D Boukens, Aimee L Phelps, et al.
Biomedicines|January 21, 2023
Biofilms on Indwelling Artificial Urinary Sphincter Devices Harbor Complex Microbe-Metabolite Interaction Networks and Reconstitute Differentially In Vitro by Material TypeGlenn T Werneburg, Daniel Hettel, Ava Adler, et al.
JACC. Cardiooncology|August 16, 2021
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I TrialDarryl P Leong, Tammy Cosman, Muhammad M Alhussein, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 7, 2019
Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinomaMark Warren, Michael Kolinsky, Christina M Canil, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Pageof 42